drugset / Trial / NCT05028933
IMC001 for Clinical Research on Advanced Digestive System Malignancies
NaSequentialOpen-labelTreatment
Summary
A Phase I Clinical Study of Autologous T cells modified with chimeric antigen receptor targeting EpCAM ( EPCAM CAR-T) in Patients with malignant tumors of the digestive system (including advanced gastric cancer, colorectal cancer, liver cancer and pancreatic cancer) .
Timeline
- Start
- 2021-09-30
- Primary completion
- 2024-12-30
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EPCAM CAR-T | Cell therapy | 300000 cells/kg | Intravenous |
| Subject | EPCAM CAR-T | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | EPCAM CAR-T | Cell therapy | 3e+06 cells/kg | Intravenous |